Cargando…

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials

BACKGROUND: Previous meta-analyses have compared paliperidone extended-release (ER) tablets with other antipsychotics, but none have involved Chinese patients or studies from People’s Republic of China. Further, the results of these meta-analyses may not be applicable to Chinese patients. In the pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Shangli, Lu, Huafei, Bai, Zhihua, Wu, Renrong, Zhao, Jingping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517523/ https://www.ncbi.nlm.nih.gov/pubmed/26229477 http://dx.doi.org/10.2147/NDT.S84833

Ejemplares similares

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang, Fu De, et al.
Publicado: (2017)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2008)

Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)
por: Jung, Seung-Ho, et al.
Publicado: (2013)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao, Jingping, et al.
Publicado: (2017)

Effects of paliperidone extended release on the symptoms and functioning of schizophrenia
por: Huang, Min-Wei, et al.
Publicado: (2012)

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
por: Spina, Edoardo, et al.
Publicado: (2011)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas, Apichat, et al.
Publicado: (2017)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
por: Wang, Gang, et al.
Publicado: (2020)

Tablets of paliperidone using compression-coated technology for controlled ascending release
por: Tang, Yingying, et al.
Publicado: (2018)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa, Ryoko, et al.
Publicado: (2015)

Treatment of bipolar mania with paliperidone extended-release
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si, Tianmei, et al.
Publicado: (2019)

Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence
por: Si, Tianmei, et al.
Publicado: (2018)

Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study
por: Wang, Gang, et al.
Publicado: (2019)

Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia
por: Helldin, Lars, et al.
Publicado: (2015)

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Canuso, Carla M, et al.
Publicado: (2010)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino, Jehan, et al.
Publicado: (2012)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
por: Li, Nan, et al.
Publicado: (2018)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang, Hongyan, et al.
Publicado: (2016)

Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study
por: Si, Tian Mei, et al.
Publicado: (2019)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
por: Si, TianMei, et al.
Publicado: (2015)

Paliperidone extended-release: does it have a place in antipsychotic therapy?
por: Gahr, Maximilian, et al.
Publicado: (2011)

Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder
por: Yamamuro, Kazuhiko, et al.
Publicado: (2014)

Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia
por: Kongsakon, Ronnachai, et al.
Publicado: (2017)

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
por: Okuda, Darin T, et al.
Publicado: (2022)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2008)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2009)

The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia
por: Guo, Xiaofeng, et al.
Publicado: (2013)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
por: Chen, Ching-Yen, et al.
Publicado: (2018)

Additive Manufacturing of an Extended-Release Tablet of Tacrolimus
por: Abdollahi, Azin, et al.
Publicado: (2023)

Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial
por: Kang, Nam-In, et al.
Publicado: (2016)

Paliperidone: the evidence of its therapeutic value in schizophrenia
por: Kantrowitz, Joshua, et al.
Publicado: (2007)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
por: Markowitz, Michael, et al.
Publicado: (2013)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
por: Shi, Chuan, et al.
Publicado: (2016)

Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study()
por: Pandina, Gahan, et al.
Publicado: (2020)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
por: Zhang, LiLi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jbr0va5fc7fhouuckekb3m5ga0